Diaceutics PLC
DXRX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.23 | -0.01 | 0.85 |
| FCF Yield | 1.11% | -0.51% | 1.34% | 0.75% |
| EV / EBITDA | -30.14 | 23.46 | -95.80 | 24.71 |
| Quality | ||||
| ROIC | -6.80% | 1.78% | -7.09% | -1.08% |
| Gross Margin | 82.99% | 88.41% | 69.91% | 79.90% |
| Cash Conversion Ratio | -0.25 | -0.57 | -0.58 | -2.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 29.69% | 28.81% | 22.91% | 21.96% |
| Free Cash Flow Growth | 201.85% | -137.50% | 162.30% | 127.52% |
| Safety | ||||
| Net Debt / EBITDA | 6.90 | -2.90 | 16.25 | -6.61 |
| Interest Coverage | -115.45 | 43.46 | -128.32 | -35.21 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 31.25 | 20.23 | 55.93 | 31.54 |